Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
Data updated
Papers
Trials
Research Footprint
Attila Szabo appears in 11 tracked papers (2013–2023), most studied alongside DMT, 5-MeO-DMT and Psilocybin, across Immunology & Inflammation, Depressive Disorders and Substance Use Disorders (SUD).
Most-cited paper: Psychedelic N,N-Dimethyltryptamine and 5-Methoxy-N,N-Dimethyltryptamine Modulate Innate and Adaptive Inflammatory Responses through the Sigma-1 Receptor of Human Monocyte-Derived Dendritic Cells (189 citations).
Frequent co-authors: Ede Ottó Frecska, Johannes Ramaekers and Michael Winkelman.
Background & Research
Attila Szabo has published on the immune and neuroprotective effects of psychedelics, especially DMT, 5-MeO-DMT, and psilocybin. His papers link psychedelic compounds to sigma-1 receptor biology, inflammatory signaling, and psychoneuroimmunology. Recent publication metadata indicates an affiliation with the University of Oslo. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/25171370/?utm_source=openai))
Key Impact
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Collaboration Network
19 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Attila Szabo is associated with.